æther THERAPEUTICS

æther THERAPEUTICS

Addressing the opioid crisis: æther THERAPEUTICS is developing Low Dose 6β-Naltrexol (ATX-001). Animal models indicate that ATX-001 may prevent opioid dependence while not blocking pain relief or causing withdrawal & other adverse effects. æther THERAPEUTICS is an impact investment opportunity.

Print
Claim My Business
Security Type
Common Stock
Min Investment
$99
Location
Austin, TX
Offering Date
August 21, 2024
Expected Close Date
December 06, 2024
Target Raise
$10.00K-$800.03K
Security Price
$3.68
Valuation
$17,486,944
Number of Employees
3
Cash
$176,687
Revenue
$0
Short Term Debt
$0
Cost of Goods
$0
Long Term Debt
$0
Net Income
$147,198

Company Description

The statistics are overwhelming: more than 130 people a day die from opioid related drug overdoses. In 2020 in the US alone, 2.7 million people aged 12 or older suffered from Opioid Use Disorder (OUD) and 4.2 million people entered a drug rehabilitation program.While therapy programs and rescue medications are critical, æther THERAPEUTICS is focusing our efforts upstream: preventing addiction and creating a more effective treatment of OUD. Our vision is a world where the devastating effects of opioid addiction are alleviated, leading to: Safer opioid pain therapy without the fear of addictionReversal of opioid addiction Prevention of Neonatal Opioid Withdrawal Syndrome (NOWS) æther THERAPEUTICS is focused on our vision, driven by innovation, while embracing lean operations and engaging with urgency.

Management Team / Advisory Board Bios

Wolfgang Sadee, PhD
Founder & Chief Science Officer
A globally respected thought leader in opioid pharmacology, Dr. Wolfgang Sadee is a founder of æther THERAPEUTICS and serves as Chief Science Officer. Dr. Sadee is also Professor emeritus of Cancer Biology and Genetics, College of Medicine, at the Ohio State University, and Professor emeritus of Bioengineering and Therapeutic Sciences, Colleges of Pharmacy and Medicine, at the University of California San Francisco. Dr. Sadeeʼs prolific research (well over 400 research papers and monographs) has focused on opioid pharmacology, therapeutics, pharmacogenomics, drug response and toxicity.


https://www.linkedin.com/in/wolfgang-sadee-bb39ab10/



John D. Harris
President & Chief Executive Officer
Joining æther THERAPEUTICS in July 2022 as CEO, Mr. Harris brings the critical skillsets, focus and experience to successfully propel the development of ATX-001. Prior to æther, he was the CEO of balboa RESEARCH SMO+, a leading clinical research organization, executing over 50 clinical trials. Mr. Harrisʼ background at large, medium and start-up organizations in the biotech and cell therapy fields provide deep operational, executive and market development savvy.

https://www.linkedin.com/in/john-d-harris-5494156/




Jon S. Saxe
Chairman of the Board
Chairman of the æther THERAPEUTICS Board of Directors, Jon Saxe brings a wealth of experience, having served on over 25 Boards with multiple successful exits. Mr. Saxe was the Vice President, Corporate Development & Licensing, of Hoffmann-LaRoche, CEO of Synergen, President of PDL Biopharma between 1995 and 2000 and served on its board between 1989 and 2010. Currently, Mr. Saxe is the lead director of the investment entity K2X Technology and Life Sciences.

https://www.linkedin.com/in/jon-saxe-96b5385/



Bob Davis, Pharm.D
Senior Scientist, Clinical & Regulatory
With a career spanning over 38 years, Bob Davis has deep experience in developing drugs, biologicals and medical devices as a part of Contract Research Organizations(CROs) and pharmaceuticals. He has been involved in spearheading development of two small molecules and one biological from inception through FDA approval. Dr. Davis led the submission of the first electronically filed NDA to the Endocrine Division in 1999 and has been involved in the creation, monitoring and/or advising of the conduct of over 200 clinical protocols.

https://www.linkedin.com/in/bob-davis-755367b/




John McKew, PhD
Technical Advisor
John McKewʼs tremendous background with the NIH (Chief @ National Center for Advancing Translational Sciences & Director @ Translational Therapeutics) and deep biotech chops (Head of Research @ Tyr Pharma and President of Lumos Pharma) is a tremendous asset to æther THERAPEUTICS.

https://www.linkedin.com/in/johncmckew/



Rick Hawkins
Founder
Rick Hawkins is a 40 year veteran in the biotechnology field and has founded/co-founded three companies that were successfully sold (Pharmaco to PPD; Sensus to Pfizer; Covance to Azko Nobel). In addition to his keen interest in æther THERAPEUTICS, Mr. Hawkins currently runs both ID2 (a pharmaceutical accelerator) and Lumos Pharma, in his role of CEO and Chairman.

https://www.linkedin.com/in/rickhawkins-lumos/
Amount Raised : $15,357
Reveal the Score by Voting
_
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.
Valuation

Security Description

Common stock is a security that represents ownership in a corporation.

Research Reports

No reports have been submitted

Become a Reporter

0 Comments